Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
about
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium RetentionPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyGlucose supply and insulin demand dynamics of antidiabetic agents.The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsPioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats.Metabolic syndrome in the Mediterranean region: Current statusAtherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.Update on the protective molecular pathways improving pancreatic beta-cell dysfunctionBanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusPioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes.Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY.Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway.
P2860
Q26851905-4A7B5E53-65D8-46B6-A4D9-C9ECE18BF761Q27024799-544EDC60-0B85-4F31-83D8-25D6366748CAQ33828255-0F24EFF1-4949-4A0C-8EEC-C20E03CC8BCAQ33888236-DB72FABD-124D-4968-AA02-D8F5622F7439Q34133889-7252A6BA-C018-4431-817D-D34C53172260Q34139048-65C4AFB2-298B-426D-AC51-EAD9B4ADB695Q34671018-8F1C82B9-75D3-4B72-BC8B-3EEBC8D2F6FDQ35686365-5103AA89-B8DC-43CC-B473-D0C3278B5A0EQ36851491-FCDBB59A-AB92-441A-8983-A2762E77E09BQ36860811-C75A06BC-59F8-4B67-B09A-885488E2ACCFQ37141727-EF3DA562-AA05-43BF-96F2-0B0122E8D4E8Q37537808-D257F99B-6365-417D-99B5-91B1DB9E0958Q37577126-5E309BD9-53D3-4550-AC3C-F4193134B466Q37577162-EE8877D0-5263-4054-BC6A-695519D30E29Q37690079-68A56D74-EE88-408A-B9BB-18CEED4ED457Q37709423-47413BE7-B184-4F2E-B0B4-B5661AE0DCCCQ38725752-B7CBB06C-F475-42A7-BE2F-1C9616DA172CQ44108133-0350D8D6-201B-4FBA-9FD1-308001778A40Q46704551-0F88B459-D231-42A4-AFF8-D484CB23FC19Q51283845-F466F73B-9496-44B1-84C7-AA5BF8629C1FQ54201255-8DD002A5-2987-4DDE-875F-26AAE9479FEF
P2860
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@en
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@nl
type
label
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@en
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@nl
prefLabel
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@en
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@nl
P2860
P1476
Rosiglitazone and pioglitazone ...... s in type 2 diabetic patients.
@en
P2093
R A DeFronzo
Y Miyazaki
P2860
P304
P356
10.1111/J.1463-1326.2008.00880.X
P577
2008-05-12T00:00:00Z